Abeona Therapeutics Inc
Închisă
5.62 -1.92
Rezumat
Modificarea prețului
24h
Minim
5.61
Maxim
5.83
Venit | 3.4M -17M |
|---|---|
Vânzări | 3.3M 8.7M |
P/E Medie Sector | 5.894 50.958 |
Marjă de profit | -195.814 |
Angajați | 226 |
Recomandări | Puternic Cumpărare |
|---|---|
Prognoză pe 12 luni | +245.28% upside |
Următoarele câștiguri | 13 aug. 2026 |
|---|
Capitalizare de piață | -4.4M 279M |
|---|---|
Deschiderea anterioară | 7.54 |
Închiderea anterioară | 5.62 |
Abeona Therapeutics Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Despre Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
